<DOC>
	<DOCNO>NCT02633761</DOCNO>
	<brief_summary>The primary aim trial compare efficacy mifepristone-misoprostol versus misoprostol alone treatment intrauterine fetal demise 14 28 week LMP .</brief_summary>
	<brief_title>Mifepristone-misoprostol vs. Misoprostol Alone Second Trimester Fetal Death</brief_title>
	<detailed_description>The primary aim trial compare efficacy mifepristone-misoprostol versus misoprostol alone treatment intrauterine fetal demise 14 28 week LMP . This randomized control double-blinded trial 150 woman compare misoprostol alone mifepristone plus misoprostol evacuation uterus fetal demise second third trimester . All woman trial undergo routine screen pre-medical induction care per standard practice hospital . All eligible woman agree participate study randomize receive one follow regimen : 1 . STUDY GROUP ONE : 200mg mifepristone follow 24 hour repeat dos 200mcg buccal misoprostol give every 3 hour ; 2 . STUDY GROUP TWO : placebo follow 24 hour 200mcg buccal misoprostol give every three hour .</detailed_description>
	<mesh_term>Death</mesh_term>
	<mesh_term>Fetal Death</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<criteria>Demised fetus 14 28 week duration confirm ultrasound Have contraindication study procedure , accord provider Be able consent procedure , either read consent document consent document read Be willing follow study procedure . Allergies contraindication use mifepristone misoprostol ; Placental abruption active hemorrhage , Complete placenta previa , extreme uterine structural anomaly , contradiction vaginal delivery fetus ; Presentation active labor ( moderate severe contraction every 10 minute less ) ; Transmural uterine scar ; Four previous delivery .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Fetal death</keyword>
	<keyword>mifepristone</keyword>
	<keyword>misoprostol</keyword>
</DOC>